Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Declines By 24.4%

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 657,200 shares, a decline of 24.4% from the March 31st total of 868,800 shares. Based on an average daily trading volume, of 388,300 shares, the days-to-cover ratio is currently 1.7 days.

Aligos Therapeutics Stock Performance

Shares of ALGS opened at $0.78 on Friday. The stock’s fifty day moving average price is $0.91 and its two-hundred day moving average price is $0.76. Aligos Therapeutics has a 1 year low of $0.54 and a 1 year high of $1.38.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05. The company had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $3.20 million. Aligos Therapeutics had a negative return on equity of 116.41% and a negative net margin of 607.03%. As a group, analysts forecast that Aligos Therapeutics will post -0.83 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Newtyn Management LLC boosted its holdings in shares of Aligos Therapeutics by 2.2% in the 3rd quarter. Newtyn Management LLC now owns 920,000 shares of the company’s stock worth $687,000 after purchasing an additional 20,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Aligos Therapeutics by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,010,617 shares of the company’s stock worth $755,000 after purchasing an additional 15,905 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Aligos Therapeutics in the 4th quarter valued at about $861,000. Altitude Crest Partners Inc. bought a new stake in shares of Aligos Therapeutics in the 4th quarter valued at about $1,889,000. Finally, Armistice Capital LLC bought a new stake in shares of Aligos Therapeutics in the 4th quarter valued at about $4,538,000. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).